April 27 (Reuters) - Geneuro SA ::Top-Line results from phase IIb multiple sclerosis trial expected early Q4 2017.Cash and cash equivalents amounted to EUR 34.5 million at December 31, 2016, compared with EUR 18.6 million at December 31, 2015.FY operating revenues EUR 5.9 million versus EUR 2.5...
April 27 (Reuters) - Celgene Corp :Celgene reports first quarter 2017 operating and financial results.Q1 revenue rose 18 percent to $2.96 billion.Q1 earnings per share $1.16.Celgene corp - raising 2017 eps guidance.Celgene corp - positive phase ii stepstone data with ozanimod in crohn's disease;...
April 24 (Reuters) - SillaJen Inc ::SillaJen and Transgene announce the enrollment of the first European patient in multinational Phase 3 trial for Pexa-Vec in advanced liver cancer.Enrollment of the first European patient triggers a $4 million USD milestone to be paid to Sillajen by Transgene.
April 24 (Reuters) - Atyr Pharma Inc :Atyr Pharma announces promising top-line results from Resolaris phase 1B/2 clinical trial in patients with early onset facioscapulohumeral muscular dystrophy.Resolaris generally well-tolerated at doses up to 3.0 mg/kg once weekly in early onset...
No related earnings announcements are currently scheduled within the next 7 days.